There is an unmet need for a noninvasive biomarker in renal cell carcinoma. KIM-1 has emerged as a compelling candidate according to retrospective evidence and post hoc analyses of prospective trials. Prospective studies are needed for validation and clinical implementation.
European urology focus. 2025 Jul 05 [Epub ahead of print]
Clara Steiner, Marc Machaalani, Joseph V Bonventre, David F McDermott, Toni K Choueiri, Wenxin Xu
Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Harvard Medical School, Boston, MA, USA; Brigham and Women's Hospital, Boston, MA, USA., Harvard Medical School, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA, USA., Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address: .